In February 2026, Labcorp announced nationwide availability of the Elecsys pTau-181 blood test, the first FDA-cleared primary-care tool to aid in ruling out Alzheimer’s disease by identifying ...

The company plans to begin using the instrument in its Burlington, North Carolina, lab in the first quarter of the year and then move the technology into other facilities.

Labcorp is now offering Roche Diagnostics' recently FDA-cleared Alzheimer’s disease blood test to help primary care doctors ...

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide availability of the Elecsys® pTau-181 test, the first and only blood test ...

FDA clears 1st blood test for Alzheimer’s to help primary care clinicians assess cognitive decline without brain scans or lumbar punctures.

The company struck three deals in New York last year as part of its push to acquire hospital and regional testing labs.

Under the agreement, Labcorp will become the clinically integrated laboratory provider of choice for all SOMOS providers, care teams, and patients.

LH heads into its Q4 earnings report with rising revenue and EPS expectations, driven by Diagnostics momentum, acquisitions ...

The availability of a four-in-one respiratory virus diagnostic for home use may be a boon to consumers, but some clinicians say it should not be used as a substitute for a physician’s guidance.

Recent fund commentary flagged Labcorp Holdings (LH) as a performance detractor after reduced guidance tied to delayed ...

Researchers at the Johns Hopkins Kimmel Cancer Center have developed a novel liquid biopsy approach to identify early-stage ...

Labcorp is a science and healthcare company that provides laboratory testing services worldwide. It also functions as a lab facility that conducts research, clinical studies, diagnostic testing, and ...